RGC

RGC AI+
Andrew 10-03 Regencell Bioscience Holdings Limited Public
US:RGC

How much of RGC Bio Float is shorted naked

Rate this post:
0
Kommentarer (3)
AI+ Standard 10-03
Dette svar blev genereret af AI. Selvom vi stræber efter nøjagtighed, kan det indeholde fejl.

While direct data on "naked shorting" is not publicly available, as it refers to an illegal practice of short selling shares without first borrowing them or determining that they can be borrowed, we can analyze related metrics to understand short selling pressure on Regencell Bioscience Holdings Limited (RGC). "Fails-to-deliver" (FTDs) are often considered a proxy for potential naked shorting, as they represent a failure to deliver shares on the settlement date.

Based on Fintel's data for RGC:

  • Reported Short Interest: As of the latest NASDAQ data, the reported short interest for RGC is 1,822,668 shares.
  • Short Interest as % of Float: This represents 9.89% of the company's float, indicating a moderate level of short selling relative to the available shares for trading.
  • Days to Cover: The short interest ratio, or days to cover, stands at 7.24 days. This metric suggests it would take approximately 7.24 trading days for short sellers to cover their positions, given the average daily trading volume.
  • Off-Exchange Short Volume: On August 6, 2025, the off-exchange short volume for RGC was 74,241 shares, with an off-exchange short volume ratio of 64.53%. This indicates a significant portion of short selling activity occurring off traditional exchanges, including dark pools.
  • Borrow Rate: The borrow rate for RGC is notably high at 176.76%. A high borrow rate typically signals strong demand to short the stock and/or limited availability of shares to borrow.
  • Fails-to-Deliver (FTD): While Fintel tracks Fails-to-Deliver data, the current information for RGC does not show any recent FTD quantities in the provided snippets. FTDs are cumulative and represent shares that were not delivered by the settlement date. The absence of recent FTD data in the table suggests that there haven't been significant reported failures to deliver for RGC in the recent past.

In summary, while there's no direct measure of "naked shorting," RGC exhibits a moderate short interest percentage of float and a high borrow rate, which points to considerable interest from short sellers. However, there are no readily apparent Fails-to-Deliver data points that would typically be associated with persistent naked short selling activity.

Rate this response:
0

Andrew 10-03

Compare RGC's short interest metrics and borrow rate against its industry peers to contextualize the current short selling pressure.


AI+ Standard 10-03
Dette svar blev genereret af AI. Selvom vi stræber efter nøjagtighed, kan det indeholde fejl.

Comparing Regencell Bioscience Holdings Limited (RGC) against its industry peers provides valuable context for its short interest metrics and borrow rate, as you rightly suggested. RGC operates within the Biotechnology sector, focusing on Traditional Chinese Medicine for neurocognitive disorders.

Here’s a comparison of RGC's short interest and borrow rate against a few notable biotechnology peers:

  • Regencell Bioscience Holdings Limited (RGC):

  • Short Interest % Float: 9.89%

  • Days to Cover: 7.24 days

  • Borrow Rate: 176.76%

  • Iovance Biotherapeutics, Inc. (IOVA):

  • Short Interest % Float: 35.19%

  • Days to Cover: Not explicitly provided in the snippet

  • Borrow Rate: Not explicitly provided in the snippet

  • AVITA Medical, Inc. (RCEL):

  • Short Interest % Float: 21.82%

  • Days to Cover: 30.78 days

  • Borrow Rate: Not explicitly provided in the snippet

  • Apellis Pharmaceuticals, Inc. (APLS):

  • Short Interest % Float: 21.11%

  • Days to Cover: 4.80 days

  • Borrow Rate: Not explicitly provided in the snippet

Key Observations:

  • Short Interest % Float: RGC's short interest as a percentage of float (9.89%) is notably lower compared to IOVA (35.19%), RCEL (21.82%), and APLS (21.11%). This suggests that while RGC does have short interest, it is not as heavily shorted relative to its available shares as some of its biotechnology counterparts.
  • Days to Cover: With 7.24 days to cover, RGC falls in the middle of this peer group, higher than APLS (4.80 days) but significantly lower than RCEL (30.78 days). This indicates a moderate time frame for short sellers to close their positions.
  • Borrow Rate: The most striking difference is RGC's exceptionally high borrow rate of 176.76%. This is a critical indicator, as such a high rate typically signals intense demand to short the stock and/or a very limited supply of shares available for borrowing in the market. While specific borrow rates for the other peers were not immediately available in the provided snippets, a rate of this magnitude for RGC stands out and suggests unique market dynamics for the stock.

This comparison highlights that while RGC's short interest percentage might not be the highest in its sector, the extremely high borrow rate points to a significant cost for short sellers, which could be a factor to watch for potential short squeeze scenarios if positive catalysts emerge. Investors can explore these metrics for any stock on Fintel's Short Interest page by searching for the ticker symbol.

Rate this response:
0

Dette emne er udløbet. Det er nu låst for kommentarer.

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista